

Food and Drug Administration
Center for Drug Evaluation and Research
Pediatric Oncology Subcommittee of the
Oncologic Drugs Advisory Committee Meeting
FDA White Oak Campus, Building 31, the Great Room, White Oak Conference Center
(Rm. 1503), Silver Spring, MD
November 1, 2011

MEETING ROSTER

DESIGNATED FEDERAL OFFICER (Non-Voting)

Caleb Briggs, Pharm.D.

Division of Advisory Committee and Consultant Management
Office of Executive Programs
Center for Drug Evaluation and Research

ONCOLOGIC DRUGS ADVISORY COMMITTEE MEMBERS (Voting)

Frank Balis, M.D. (Acting Chairperson)

The Louis and Amelia Canuso Family Endowed
Chair for Clinical Research in Oncology
The Children's Hospital of Philadelphia
University of Pennsylvania School of Medicine
Philadelphia, Pennsylvania

Mikkael Sekeres, M.D., M.S.

Associate Professor of Medicine
Staff
Cleveland Clinic Taussig Cancer Institute
Department of Hematologic Oncology and
Blood Disorders
Cleveland, Ohio

Ralph Freedman, M.D., Ph.D.

Clinical Professor
Department of Gynecologic Oncology
The University of Texas
M.D. Anderson Cancer Center
Houston, Texas

**ACTING INDUSTRY REPRESENTATIVE TO THE SUBCOMMITTEE
(Non-Voting)**

Gregory Curt, M.D. (Sessions 1, 2 and 3 Only)

(Acting Industry Representative)

U.S. Medical Science Lead, Emerging Products
AstraZeneca Oncology
Garrett Park, Maryland

Food and Drug Administration
Center for Drug Evaluation and Research
Pediatric Oncology Subcommittee of the
Oncologic Drugs Advisory Committee Meeting
FDA White Oak Campus, Building 31, the Great Room, White Oak Conference Center
(Rm. 1503), Silver Spring, MD
November 1, 2011

MEETING ROSTER (cont.)

TEMPORARY MEMBERS (Voting)

Carola Arndt, M.D. (Sessions 2, 3 and 4 Only)

Professor of Pediatrics
College of Medicine
Mayo Clinic
Rochester, Minnesota

Richard Gorlick, M.D.

Vice Chairman
Division Chief, Pediatric Hematology-Oncology
Department of Pediatrics
The Children's Hospital at Montefiore
Bronx, New York

Craig Lustig

(Patient Representative)

Washington, District of Columbia

Leo Mascarenhas, M.D., M.S. (Sessions 2, 3 and 4 Only)

Associate Professor of Pediatrics
Keck School of Medicine/University of
Southern California
Director -Clinical Trials Office
Children's Center for Cancer and Blood Diseases
Childrens Hospital Los Angeles
Los Angeles, California

Kathleen Neville, M.D., M.S.

Director, Experimental Therapeutics in Pediatric
Oncology Program
Associate Professor of Pediatrics
Divisions of Pediatric Clinical Pharmacology
and Pediatric Hematology/Oncology
Children's Mercy Hospitals and Clinics
Kansas City, Missouri

Nita Seibel, M.D. (Sessions 1 and 2 Only)

Senior Investigator
Head, Pediatric Solid Tumor Therapeutics
Clinical Investigations Branch
Cancer Therapy Evaluation Program
Division of Cancer Treatment and Diagnosis
National Cancer Institute
Bethesda, Maryland

Patricia Shearer, M.D., M.S.

Professor of Pediatrics
Division Chief, Pediatric Hematology/Oncology
University of Maryland Greenebaum Cancer
Center
Baltimore, Maryland

Susan Shurin, M.D.

Acting Director, National Heart, Lung and
Blood Institute
National Institutes of Health
Bethesda, Maryland

Malcolm Smith, M.D., Ph.D. (Sessions 1 and 2 Only)

Associate Branch Chief for Pediatrics
Cancer Therapy Evaluation Program
National Cancer Institute
Rockville, Maryland

Food and Drug Administration
Center for Drug Evaluation and Research
Pediatric Oncology Subcommittee of the
Oncologic Drugs Advisory Committee Meeting
FDA White Oak Campus, Building 31, the Great Room, White Oak Conference Center
(Rm. 1503), Silver Spring, MD
November 1, 2011

MEETING ROSTER (cont.)

FDA PARTICIPANTS (Non-Voting)

Richard Pazdur, M.D.

Director, Office of Hematology Oncology
Products (OHOP)
Office of New Drugs (OND)
CDER, FDA

Melissa S. Tassinari, Ph.D., DABT

Senior Clinical Analyst
Pediatric and Maternal Health Staff
OND, CDER, FDA

Greg Reaman, M.D.

Associate Director for Oncology Sciences
OHOP, OND, CDER, FDA

Kristen Snyder, M.D. (Session 1 Only)

Medical Officer
Division of Hematology Products (DHP)
OHOP, OND, CDER, FDA

Amy McKee, M.D. (Session 2 Only)

Acting Medical Team Leader
Division of Oncology Products 1 (DOP1)
OHOP, OND, CDER, FDA

Amir Shahlaee, M.D. (Sessions 3 and 4 Only)

Medical Officer
Division of Oncology Products 2 (DOP2)
OHOP, OND, CDER, FDA